Evidence map›Paper›PMID 34681268›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Esculetin Provides Neuroprotection against Mutant Huntingtin-Induced Toxicity in Huntington's Disease Models.

Letizia Pruccoli, Carlo Breda, Gabriella Teti, Mirella Falconi, Flaviano Giorgini, Andrea Tarozzi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Esculetin attenuates cerebral ischemia-reperfusion injury and protects neurons through Nrf2 activation in rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Letizia PruccoliDepartment for Life Quality Studies, University of Bologna, 47921 Rimini, Italy.ORCID 0000-0002-0739-2102
Carlo BredaDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Gabriella TetiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.
Mirella FalconiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy.
Flaviano GiorginiDepartment of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK.
Andrea TarozziDepartment for Life Quality Studies, University of Bologna, 47921 Rimini, Italy.ORCID 0000-0001-7983-8575
University of Bologna · ITUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is a neurodegenerative disorder caused by an abnormal CAG trinucleotide repeat expansion within exon 1 of the huntingtin (HTT) gene. This mutation leads to the production of mutant HTT (mHTT) protein which triggers neuronal death through several mechanisms. Here, we investigated the neuroprotective effects of esculetin (ESC), a bioactive phenolic compound, in an inducible PC12 model and a transgenic

Indexed as

Drosophila melanogasteresculetinhuntingtinHuntington’s diseasemitochondrial dysfunctionneuroprotectionoxidative stress

Identifiers

PMID34681268
PMCPMC8541026
OpenAlexW3206073624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.